Troikaa Pharmaceuticals

What Troikaa Pharmaceuticals does

Troikaa Pharmaceuticals Limited is a privately held, family-controlled Indian pharmaceutical manufacturer founded in 1983 and headquartered in Ahmedabad, Gujarat. The company designs, manufactures, and markets branded finished-dosage pharmaceutical products built on proprietary Novel Drug Delivery Systems (NDDS), serving hospitals, surgical centers, and healthcare providers across pain management, anesthesiology/critical care, cardiology, gynecology, diagnostics, and nutraceuticals. It operates three WHO-GMP/PIC/S/ANVISA/INVIMA-accredited manufacturing facilities in India (Thol, Dehradun, Virochannagar) and reports products marketed in 120+ countries with international business spanning 92+ countries across Asia, Africa, Latin America, and CIS.

The technical core is a set of in-house drug-delivery platforms that reformulate known molecules to improve solubility, bioavailability, onset, or route of administration — AquaTech (aqueous injectable diclofenac / Dynapar AQ), QPS/Quick Penetration Solution (transdermal diclofenac Dynapar QPS and topical heparin Phlebotroy QPS), NASOMAX (nasal B12), Duo Phase (biphasic extended-release acetaminophen Xykaa Extend), Dechunking/decompactage (rapid-onset Xykaa Rapid), SEDDS/LiquiCaps (Vitamin D3), and nanoemulsion technology (propofol Troypofol). The company reports 12 globally patented innovations and 812 patent applications, 1,430 trademark applications, and 50+ brands, with an R&D department recognized by India's DSIR and a stated 6–10 year concept-to-commercialization cycle for patented products.

The business monetizes primarily through sales of branded pharmaceutical products via direct domestic field sales in India and a global sales/regulatory-affairs organization operating through wholly owned regional entities in the Philippines, Kazakhstan, Peru, Vietnam, and the Czech Republic. Secondary revenue mechanics include out-licensing and in-licensing of novel products/technologies to multinational and regional partners, and regulated international distribution. An API subsidiary, Troikaa Pharmachem Pvt. Ltd., supports backward integration. Pricing is not publicly disclosed and is effectively quote/tender-based given the regulated, volume-dependent nature of pharmaceutical procurement.

Name

Troikaa Pharmaceuticals

Legal name

Troikaa Pharmaceuticals Limited

Website

https://troikaa.com

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Ahmedabad-based private Indian pharmaceutical manufacturer specializing in Novel Drug Delivery Systems. It develops and sells patented reformulations of known molecules across pain, anesthesia, cardiology, and nutraceuticals to hospitals and healthcare providers in 120+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing (Novel Drug Delivery Systems)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industries

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Novel drug delivery
• Pharmaceutical manufacturing
• Injectable formulations
• Transdermal solutions
• Nasal drug delivery

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Core revenue stream from manufacturing and selling pharmaceutical products globally through domestic and international markets. Products include injectables, transdermal solutions, nasal sprays, sublingual formulations, and oral dosage forms in therapeutic areas of Pain Management, Gynaecology, Critical Care, Anesthesiology, Cardiology, and Nutraceuticals.
2. Out-licensing and In-licensing: Revenue from licensing novel products and technologies to partners. Troikaa creates successful marketing models across geographies for companies who wish to license their novel products/technologies, profiting from domestic and international sales and marketing teams.
3. International Distribution: Revenue from supplying products to more than 92 countries across Asia, Africa, Latin America, and CIS regions through regulatory-compliant distribution networks.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Troikaa Pharmaceuticals manufactures and sells innovative pharmaceutical products built on proprietary Novel Drug Delivery Systems (NDDS), including aqueous injectables, transdermal solutions, nasal sprays, sublingual formulations, and controlled-release oral dosages across pain management, anesthesiology, critical care, cardiology, and nutraceuticals. It markets 50+ branded products in over 120 countries.

Product overview

Troikaa Pharmaceuticals is an innovation-driven pharmaceutical company founded in 1983, specializing in Novel Drug Delivery Systems (NDDS). Its product portfolio centers on patented drug delivery technologies — including the Aquatech injectable platform, QPS (Quick Penetration Solution) transdermal system, NASOMAX nasal delivery system, Duo Phase extended-release technology, and LiquiCaps self-emulsifying encapsulation — across therapeutic segments including Pain Management (Dynapar AQ, Dynapar QPS, Xykaa Extend, Xykaa Rapid), Critical Care / Anesthesiology (Troypofol, Sevotroy, Zolswift-SL), Cardiology (Myonit Insta), Hematology (Phlebotroy QPS), Diagnostics (Troyhexol), and Nutraceuticals (Naso B12, Troyvit D3, Citrazinc SR). The company operates three state-of-the-art manufacturing facilities across India and distributes its products in over 120 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Dynapar AQ: New Diclofenac injectable using AquaTech technology; delivers full 75mg dose in 1ml with painless injection.
• Dynapar QPS
• Phlebotroy QPS
• Naso B12
• Sevotroy
• Troypofol
• Xykaa Extend
• Xykaa Rapid
• Myonit Insta
• Zolswift-SL
• Troyhexol
• Troyvit D3

Products and services

• Dynapar AQ A diclofenac injectable formulated using the proprietary AquaTech process, delivering the full 75 mg dose in just 1 mL with minimal viscosity for near-painless intradeltoid, intragluteal, or IV administration. Used in hospitals and clinical settings for post-operative and acute pain.
• Dynapar QPS The world's first transdermal diclofenac preparation using Quick Penetration Solution (QPS) technology, providing fast analgesia for musculoskeletal pain without requiring oral analgesics.
• Phlebotroy QPS A topical heparin solution (1000 IU/mL) using patented QPS technology for superior skin penetration, used for prevention and treatment of superficial thrombophlebitis and maintenance of AV fistula patency in dialysis patients.
• Naso B12 A nasal methylcobalamin spray using the proprietary NASOMAX nasal delivery system to achieve effective systemic delivery of vitamin B12 via the nasal route, formulated at 500 mcg per 0.1 mL.
• Sevotroy An optimally-hydrated sevoflurane formulation designed to prevent degradation into hydrofluoric acid, indicated for induction and maintenance of general anesthesia in adult and pediatric patients undergoing inpatient or outpatient surgery.
• Troypofol A propofol injectable nanoemulsion manufactured using high-speed homogenization to produce a uniform, controlled droplet size for improved efficacy and reduced injection pain, used for general anesthesia.
• Cyanide Antidote Kit A cyanide poisoning treatment kit providing amyl nitrite for inhalation and intravenous sodium nitrite injection, followed by sodium thiosulfate to convert cyanide-methemoglobin to thiocyanate for renal excretion.
• Xykaa Extend Biphasic extended-release acetaminophen (paracetamol) tablets (650 mg and 1000 mg) using Duo Phase Technology, where a portion of the dose is released immediately and the remainder in a prolonged manner to maintain therapeutic levels.
• Xykaa Rapid Rapid-acting paracetamol tablets using decompactage (dechunking) technology that rapidly breaks granules into fine micro-particles, enabling absorption in approximately 45 seconds and pain relief in under 20 minutes.
• Myonit Insta A rapid-acting nitroglycerin sublingual formulation with onset of action within 114 seconds, presented in amber glass vials to maintain drug potency throughout shelf life, for angina relief.
• Citrazinc SR Sustained-release zinc supplement tablets using matrix polymer technology that controls the release of zinc in small, continuous quantities over an extended period.
• Troyvit D3 Cholecalciferol (Vitamin D3) capsules using LiquiCaps technology combined with a self-emulsifying drug delivery system (SEDDS) that converts vitamin D3 into a hydrophilic soluble form for enhanced oral bioavailability.
• Zolswift-SL The world's first sublingual zolpidem spray (3.85% w/v) for short-term insomnia treatment, achieving therapeutic blood concentrations faster than oral tablets by bypassing first-pass metabolism; patented in India, US, Europe and 100+ countries.
• Troyhexol A high-quality iodinated contrast agent containing the API iohexol, supported by a US DMF and EU-approved ASMF, manufactured under ICH and WHO-GMP compliant conditions in a fully automated sterile unit for CT, MRI, angiography, and angioplasty procedures.

Quantifiable outcome

• More than 50 brands developed in key therapeutic areas
• +5 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Two partnerships are on record, tiered core.

• Multinational Pharmaceutical Companies (Unnamed)coreStrategic or Co-development PartnerNumerous multinational and leading regional companies have partnered with Troikaa for Novel Drug Delivery Systems products. Partners license Troikaa's novel products/technologies and profit from their domestic and international sales and marketing teams, creating symbiotic relationships reflecting Troikaa's core philosophy of innovation, quality and service.
• Regional Licensing Partners (Unnamed)coreOEM/ Whitelabel/ Licensing PartnerTroikaa creates successful marketing models across geographies for companies who wish to license their novel products/technologies. They offer out-licensing and in-licensing opportunities, allowing partners to benefit from Troikaa's manufacturing capabilities and regulatory expertise.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Cipla: India-based global pharma with branded generics across respiratory, pain and critical care, strong emerging-market depth, and investments in novel inhalation drug delivery — directly comparable to Troikaa's NDDS-led strategy.
• Sun Pharmaceutical Industries: India's largest specialty/generics pharma, with branded generics, novel drug delivery, and strong global emerging-markets presence. Closely comparable on therapeutic breadth, branded formulation model, and international distribution footprint.
• Lupin Limited: Indian pharma major spanning complex generics, branded formulations, and biosimilars, with global manufacturing and a strong emerging-market footprint. Comparable on branded pharma model and integrated API-to-formulation model.
• Strides Pharma Science: Indian specialty pharma with focus on complex generics, branded generics in emerging markets, and injectable platforms. Directly comparable on emerging-market branded franchise strategy.
• Torrent Pharmaceuticals: Mid-large Indian branded pharma with strong CNS, cardio and pain franchises and emerging-market distribution. Comparable on therapeutic breadth and branded formulation model.
• Zydus Lifesciences: Indian integrated pharma with strong novel drug delivery capabilities, branded generics, and US operations. Closely comparable on NDDS-led differentiation and complex injectable manufacturing.
• Glenmark Pharmaceuticals: Indian branded-generics and specialty pharma with focus on novel molecules and drug delivery, plus extensive emerging-market presence. Comparable on innovation-led branded formulation strategy.
• Dr. Reddy's Laboratories: Indian major with branded formulations, complex generics, and proprietary injectable platforms serving global markets. Overlaps with Troikaa's pain management injectable franchise and emerging-markets channel.
• Emcure Pharmaceuticals: Mid-sized Indian pharma with branded generics, injectables, and women's health focus, plus private-equity (Bain) backing and global emerging-markets presence. Closely matches Troikaa's scale and therapeutic spread.

Emerging players

• Alkermes plc: Specialty pharma built around proprietary drug delivery and formulation technologies for CNS and pain, with comparable focus on innovative delivery platforms — though focused on US/EU regulated markets rather than emerging markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TroikaaPharmac1
• Facebookfacebook.com/troikaapharmaceuticals
• LinkedInlinkedin.com/company/troikaa-pharmaceuticals-ltd-
• Instagraminstagram.com/troikaapharmaceuticals

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Troikaa Pharmaceuticals